6 results match your criteria: "Memorial Sloan Kettering Cancer Center and New York Proton Center[Affiliation]"
Am J Clin Oncol
November 2024
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
Objectives: Recent literature has provided additional data to further individualize treatment recommendations on regional nodal irradiation (RNI) patient selection and delivery techniques, but controversies surrounding optimal RNI utilization remain, including radiation technique, modality selection, and internal mammary lymph node (IMN) inclusion. The American Radium Society (ARS) Breast Appropriate Use Criteria (AUC) Committee performed a systematic review and developed a consensus guideline to summarize recent data and provide evidence-based recommendations.
Methods: A multidisciplinary panel comprised of 15 members representing radiation oncologists, medical oncologists, and surgical oncologists specializing in the treatment of breast cancer conducted an analysis of the medical literature from January 1, 2011 to April 1, 2024.
J Thorac Dis
November 2023
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center and New York Proton Center, New York, NY, USA.
Background: Camrelizumab has been demonstrated to be a feasible treatment option for locally advanced esophageal squamous cell carcinoma (ESCC) when combined with neoadjuvant chemotherapy. This trial was conducted to investigate the effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with ESCC in daily practice.
Methods: This prospective multicenter observational cohort study was conducted at 13 tertiary hospitals in Southeast China.
Int J Radiat Oncol Biol Phys
July 2022
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center and New York Proton Center, New York, New York.
Purpose: Hypofractionated radiation therapy has been safely implemented in the treatment of early-stage non-small cell lung cancer (NSCLC) but not locally advanced NSCLC owing to prohibitive toxicities with photon therapy. Proton therapy, however, may allow for safe delivery of hypofractionated radiation therapy. We sought to determine whether hypofractionated proton therapy with concurrent chemotherapy improves overall survival.
View Article and Find Full Text PDFJ Thorac Oncol
May 2022
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Transl Lung Cancer Res
October 2021
Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Background: The biological role and clinical significance of transfer RNA-derived small RNAs (tsRNAs) remain largely unclear. The purpose of this study was to investigate the biological function, molecular mechanism, and clinical significance of tsRNA-5001a in lung adenocarcinoma.
Methods: The function of tsRNA-5001a on the growth of tumor cells was accessed by cell function experiments.
Ann Palliat Med
May 2021
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
The term oligometastases represents a clinical state of metastatic disease that is limited in the number of metastatic sites and extent of disease, and amenable to metastasis-directed surgical or ablative therapy. While metastasis-directed approaches are used for palliation, the primary goal of such treatment for patients with oligometastases is to prolong survival and the duration of cancer control. Metastasis-directed therapy, for patients with limited number of metastatic sites, has been practiced for decades, dating back to the era before chemotherapy was widely used.
View Article and Find Full Text PDF